Near-infrared spectroscopy for the determination of testosterone in thin-film composites

Journal of Pharmaceutical and Biomedical Analysis

Volumn 33, Issue 2, 2003, Pages 181-189

  Fountain, William ^a   Dumstorf, Karen ^b   Lowell, Amanda E ^a,b   Lodder, Robert A ^a,b   Mumper, Russell J ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Analytical method; Buccal; Mucoadhesive; Nondestructive; Principal component regression

Indexed keywords

TESTOSTERONE;

ANALYTIC METHOD; ARTICLE; CALIBRATION; COST EFFECTIVENESS ANALYSIS; DRUG DOSAGE FORM; DRUG INDUSTRY; FILM; HORMONE DETERMINATION; INTERMETHOD COMPARISON; MEDICAL RESEARCH; NEAR INFRARED SPECTROSCOPY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; SAMPLE; STANDARD; ULTRAVIOLET RADIATION;

EID: 0042827297     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(03)00345-5     Document Type: Article

References (32)

1. Kirsch J.D., Drennen J.K. Nondestructive tablet hardness testing by near-infrared spectroscopy: a new and robust spectral best-fit algorithm. J. Pharm. Biomed. Anal. 19:1999;351-362.
2. Wargo J.D., Drennen J.K. Near-infrared spectroscopic characterization of pharmaceutical powder blends. J. Pharm. Biomed. Anal. 14:1996;1415-1423.
3. Kirsch J.D., Drennen J.K. Determination of film-coated tablet parameters by near-infrared spectroscopy. J. Pharm. Biomed. Anal. 13:1995;1273-1281.
4. Buckton G., Yonemochi E., Yoon W.L., Moffat A.C. Water sorption and near IR spectroscopy to study the differences between microcrystalline cellulose and silicified microcrystalline cellulose before and after wet granulation. Int. J. Pharm. 181:1999;41-47.
5. Allen L. Quantitative determination of carisoprodol, phenacetin, and caffeine in tablets by near-IR spectrometry and their identification by TLC. J. Pharm. Sci. 63:1974;912-916.
6. A.S. Hussain, The process analytical technology (PAT) initiative: progress report and next steps, Process Analytical Technologies Subcommittee of the Advisory Committee for Pharmaceutical Science, Food and Drug Administration, June 12, 2002, Briefing http://www.fda.gov/ohrms/dockets/ac/02/briefing/3869b1.htm .
7. Lodder R.A., Hieftje G.M. Analysis of intact tablets by near-infrared reflectance spectrometry. Appl. Spectrosc. 42:1988;556-558.
8. Lodder R.A., Selby M., Hieftje G.M. Detection of capsule tampering by near-infrared reflectance analysis. Anal. Chem. 59:1987;1921-1930.
9. Lodder R.A., Hieftje G.M. Detection of subpopulations in near-infrared reflectance analysis. Appl. Spectrosc. 42:1988;1500-1512.
10. Aldridge P.K., Mushinsky R.F., Andino M.M., Evans C.L. Identification of tablet formulations inside blister packages by near infrared spectroscopy. Appl. Spectrosc. 48:1994;1272-1276.
11. Drennen J.K., Lodder R.A. Nondestructive near-infrared analysis of intact tablets for determination of degradation product. J. Pharm. Sci. 79:1990;622-627.
12. Niemczyk T.M., Delgado-Lopez M.M., Allen F.S. Quantitative determination of bucindolol concentration in intact gel capsules using Raman spectroscopy. Anal. Chem. 70:1998;2762-2765.
13. Dempsey R.J., Davis D.G., Buice R.G. Jr, Lodder R.A. Biological and medical applications of near-infrared spectrometry. Appl. Spectrosc. 50:1996;18A-34A.
14. Fischer M., Tran C.D. Investigation of solid-phase peptide synthesis by the near-infrared multispectral imaging technique: a detection method for combinatorial chemistry. Anal. Chem. 71:1999;2255-2261.
15. Fischer M., Tran C.D. Evidence for kinetic inhomogeneity in the curing of epoxy using the near-infrared multispectral imaging technique. Anal. Chem. 71:1999;953-959.
16. Tran C.D., Cui Y., Smirnov S. Simultaneous multispectral imaging in the visible and near-infrared region: applications in document authentication and determination of chemical inhomogeneity of copolymers. Anal. Chem. 70:1998;4701-4708.
17. Jay S., Fountain W., Cui Z., Mumper R.J. Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. J. Pharm. Sci. 91:2002;2016-2025.
18. Cui Z., Mumper R.J. Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. Pharm. Res. 19:2002;1901-1906.
19. Cui Z., Mumper R.J. Bi-layer films for mucosal (genetic) immunization via the buccal route in rabbits. Pharm. Res. 19:2002;947-953.
20. Lodder R.A., Hieftje G.M. A disposable liquid microcell for near-infrared reflectance analysis. Appl. Spectrosc. 42:1988;518-519.
21. Gambineri A., Pasquali R. Testosterone therapy in men: clinical and pharmacological perspectives. J. Endocrinol. Invest. 23:2000;196-214.
22. Rabkin J.G., Wagner G.J., Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry. 57:2000;141-147.
23. Parker S., Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men. Clin. Endocrinol. 50:1999;57-62.
24. Voorspoels J., Remon J.P., Eechaute W., De Sy W. Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs. Pharm. Res. 13:1996;1228-1232.
25. Dobs A.S., Hoover D.R., Chen M.C., Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J. Clin. Endocrinol. Metab. 83:1998;33-39.
26. Winters S.J. Current status of testosterone replacement therapy in men. Arch. Fam. Med. 8:1999;257-263.
27. Slater C.C., Souter I., Zhang C., Guan C., Stanczyk F.Z., Mishell D.R. Pharmacokinetics of testosterone after percutaneous gel or buccal administration. Fertil. Steril. 76:2001;32-37.
28. Kim S., Snipes W., Hodgen G.D., Anderson F. Pharmacokinetics of a single dose of buccal testosterone. Contraception. 52:1995;313-316.
29. Cutter C.B. Compounded percutaneous testosterone gel: use and effects in hypogonadal men. J. Am. Board Fam. Pract. 14:2001;22-32.
30. Jordan W.P. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am. J. Contact Dermatitis. 8:1997;103-113.
31. Jordan W.P., Atkinson L.E. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin. Ther. 20:1998;80-87.
32. Dobs A.S., Meikle A.W., Arver S., Sanders S.W., Caramelli K.E., Mazer N.A. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 84:1999;3469-3478.